Nuformix strategy is to optimise value from our existing assets while maintaining tight control of costs

We intend to achieve this by:

  • Progressing further preclinical work on our lead asset, NXP002, to deliver a more robust data package to potentially increase this asset’s value and attractiveness to partners/licensees
  • Pursuing licensing of NXP001; and
  • Conducting further research/patent application filing on NXP004 to provide a potential IP licensing opportunity

Business development/licensing activities for all three assets use a structured and data-driven approach, with the goal of seeking global licensing deals.

In addition, we continue to seek ongoing non-dilutive grant funding for our early-stage assets that, if successful, will enable further investment in our pipeline to accelerate development and ultimately the potential for licensing opportunities.